Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 Years - ACIP 2022

Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 Years: recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Summary
What is already known about this topic?
Immunocompromised persons experience a higher incidence of herpes zoster and related complications. On July 23, 2021, the Food and Drug Administration expanded the indication for use of recombinant zoster vaccine (RZV) to include immunodeficient or immunosuppressed adults.

What is added by this report?
On October 20, 2021, the Advisory Committee on Immunization Practices recommended 2 RZV doses for prevention of herpes zoster and related complications in immunodeficient or immunosuppressed adults aged ≥19 years.

What are the implications for public health practice?
RZV is the first herpes zoster vaccine approved for use in immunocompromised persons. With moderate to high vaccine efficacy and an acceptable safety profile, RZV has the potential to prevent considerable herpes zoster incidence and related complications.


Read full Guideline